Lipid nanoparticles are tiny fat-based delivery vehicles, typically 30 to 100 nanometers across, engineered to shuttle fragile genetic cargo like mRNA and small interfering RNA into human cells. They became a household concept almost overnight during the COVID-19 pandemic, when both the Pfizer-BioNTech and Moderna vaccines used them to deliver spike-protein-encoding mRNA. But the technology behind them traces back decades, evolving from crude lipid-DNA complexes into the precisely tuned systems that made those vaccines possible. The science is now pushing well beyond infectious disease, into gene editing, cancer therapy, and conditions once considered untreatable.
What Is Actually Inside a Lipid Nanoparticle
A standard lipid nanoparticle is built from four ingredients, each doing a specific job. The ionizable lipid is the workhorse: it carries a slight positive charge at low pH, which lets it bind to negatively charged nucleic acids during manufacturing and later helps the particle escape from inside the cell once it has been swallowed up. A helper lipid, often a phospholipid, stabilizes the particle’s structure. Cholesterol fills gaps in the lipid shell, adding mechanical rigidity. And a PEG-lipid (polyethylene glycol attached to a lipid tail) coats the outer surface, preventing the particles from clumping together and shielding them from rapid clearance by the immune system.
This four-part recipe is not set in stone, though. Researchers have found that cholesterol in conventional formulations tends to steer particles toward the liver, while PEG-lipids can trigger immune reactions after repeated dosing. One recent approach replaced both cholesterol and PEG-lipids with a new class of zwitterionic ionizable lipids, producing a three-component particle that accumulated roughly 70% less in the liver and delivered mRNA to the spleen about 4.5 times more efficiently than the standard Pfizer-BioNTech formulation.1PubMed Central. Replacing cholesterol and PEGylated lipids with zwitterionic ionizable lipids in LNPs for spleen-specific mRNA translation That kind of redesign hints at how much room still exists to optimize these vehicles for different destinations in the body.
How They Differ From Traditional Liposomes
Liposomes, hollow spheres made of lipid bilayers, have been around since the 1960s. They were the original fat-based delivery system and are still used in certain drugs. Lipid nanoparticles look similar from a distance but have a fundamentally different interior. Where a liposome is basically a tiny water-filled balloon wrapped in lipid membrane, an LNP has a more complex internal structure. Its ionizable lipids form an electron-dense core that traps nucleic acid cargo inside, rather than floating it in an aqueous center.2ACS Nano. Lipid Nanoparticles: From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement This structural difference matters for stability: mRNA enclosed inside a liposome’s watery compartment is more vulnerable to degradation than mRNA packed tightly among ionizable lipids.
The distinction also shows up in size. Solid lipid nanoparticles have been measured at around 88 nanometers in diameter compared to about 148 nanometers for corresponding liposomes carrying similar cargo.3PubMed. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes Smaller particles penetrate tissues more easily and clear differently, which makes size control important for predictable drug behavior.
Why They Head Straight for the Liver
One of the defining features of conventional lipid nanoparticles is their strong preference for the liver. Within minutes of entering the bloodstream, they pick up a protein coat from the blood, and the key player in that coat is apolipoprotein E (ApoE). ApoE essentially acts as a postal address: liver cells (hepatocytes) display receptors that recognize ApoE, so they vacuum up any particle carrying it. This is an endogenous targeting mechanism, meaning the body does the targeting work by itself.4PubMed. Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-d-galactosamine/asialoglycoprotein receptor pathway
This liver tropism was a lucky accident for the first approved LNP drug, patisiran (Onpattro), which treats a rare liver disease by silencing a gene in hepatocytes. It was also useful for the COVID-19 vaccines, where the mRNA only needed to be translated into protein somewhere in the body to trigger an immune response. But for diseases affecting the lungs, brain, or tumors outside the liver, the liver’s greedy uptake is a problem. Researchers have found that by tuning the helper lipid, they can modulate how much ApoE binds and which receptor pathways get activated, opening the door to liver-specific designs that work through alternative uptake routes.5PubMed Central. Potent Liver-Tropic mRNA Lipid Nanoparticles: ApoE-Mediated Delivery Through a Low-Density Lipoprotein Receptor Independent Uptake Mechanism
Once inside a cell, the real challenge begins. Lipid nanoparticles enter through endocytosis, essentially getting wrapped in a pocket of cell membrane that pinches off to form an internal compartment called an endosome. The cargo is trapped inside that compartment, and the endosome is on a path toward fusion with a lysosome, which would destroy everything inside. The ionizable lipid earns its keep here: as the endosome acidifies, the lipid picks up a positive charge and interacts with the negatively charged endosomal membrane, disrupting it enough for some mRNA to leak into the cytoplasm where it can be read by the cell’s protein-making machinery.6Nature Reviews Materials. Lipid nanoparticles for mRNA delivery Only a small fraction of particles manage this escape, which is why improving endosomal escape efficiency is one of the most active areas of LNP research.
Getting Past the Liver
The field’s biggest engineering challenge right now is directing lipid nanoparticles to organs other than the liver. A strategy called selective organ targeting, or SORT, demonstrated that adding a supplemental charged lipid molecule to a standard LNP formulation could redirect gene editing to the lungs, spleen, or liver depending on which lipid was added. By using permanently positively charged lipids, researchers shifted delivery to the lungs; negatively charged lipids sent particles to the spleen instead. The SORT approach achieved tissue-specific gene editing in therapeutically relevant cell types including lung epithelial cells, splenic B and T cells, and endothelial cells.7PubMed Central. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing
Inhaled delivery is another route attracting attention. For respiratory diseases, delivering LNPs directly to the lungs via nebulization or dry powder inhalers could bypass the liver entirely and concentrate the drug where it is needed, while reducing systemic side effects.8PubMed Central. Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics The engineering obstacles are significant, though: aerosolization subjects the nanoparticles to shear forces and the lungs present a sticky mucus barrier, both of which can degrade or trap the particles before they reach target cells.
The PEG Problem
PEGylated lipids are a standard ingredient in current LNP formulations because the PEG chains create a hydrophilic shield that prevents rapid immune clearance. But PEG has a downside that becomes more pressing with repeated dosing. Both the Pfizer-BioNTech and Moderna COVID-19 vaccines triggered production of anti-PEG antibodies (both IgM and IgG) in recipients, with some studies reporting greater-than-tenfold rises in anti-PEG antibody levels in roughly 10% of one vaccine’s recipients and all recipients of another.9PubMed Central. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG
For the vaccines, this turned out to be manageable. Even though anti-PEG antibodies were produced, they did not meaningfully interfere with the generation of neutralizing antibodies against the virus, meaning the vaccines still worked.10Molecular Pharmaceutics. Effect of Anti-PEG Antibody on Immune Response of mRNA-Loaded Lipid Nanoparticles But for therapies requiring many repeat doses over months or years, like gene therapies for chronic disease, anti-PEG antibodies pose a more serious concern. They can activate the complement system, compromising the structural integrity of PEGylated nanoparticles and causing premature release or exposure of cargo to serum proteins.11PubMed. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement A small percentage of people who develop extremely high anti-PEG antibody levels may be at increased risk for hypersensitivity reactions or anaphylaxis to PEGylated drugs.12PubMed Central. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG This is one reason the zwitterionic lipid replacements for PEG, mentioned earlier, are generating interest: they avoid the PEG-related immune issues entirely.
Beyond Vaccines: Gene Editing and Cancer
The mRNA vaccine application gets the most public attention, but LNPs are being developed as vehicles for an expanding list of genetic medicines. One of the most consequential is CRISPR-Cas9 gene editing, where the challenge is delivering two large RNA molecules, the Cas9 mRNA and a single guide RNA, into the same cell at the same time. Lipid nanoparticles are well suited for this because both molecules can be co-encapsulated in a single particle.
In one proof of concept, LNPs co-delivering Cas9 mRNA and guide RNA achieved specific knockdown of the Angptl3 gene in mouse livers, producing substantial drops in LDL cholesterol and triglyceride levels.13PubMed Central. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3 Because gene editing creates a permanent change in DNA, a single dose could produce lasting therapeutic effects without the need for chronic repeat dosing, which is the dream for conditions like familial hypercholesterolemia.
Cancer therapy adds another layer of complexity. Tumors are scattered throughout tissue and are not easy to reach via passive accumulation. Researchers developed antibody-targeted LNPs that could be directed at EGFR-expressing ovarian tumors. When injected into the abdominal cavity of mice, these particles achieved up to roughly 80% gene editing within the tumors, inhibited tumor growth, and increased survival by 80%.14PubMed Central. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy Zwitterionic amino lipids have also enabled co-delivery of Cas9 mRNA and guide RNA to the liver, kidneys, and lungs simultaneously in mouse models.15PubMed Central. Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA Self-amplifying RNA vaccines, which replicate their own RNA once inside the cell, have also been formulated in LNPs with substantially higher immunogenicity than unformulated RNA.16PubMed Central. Nonviral delivery of self-amplifying RNA vaccines
Toxicity at Higher Doses
The safety record of LNPs at vaccine-level doses is strong, but toxicity becomes a real concern at the higher doses needed for some therapeutic applications. In preclinical testing, lipid-siRNA nanoparticles at low doses (1 mg/kg in rats) achieved over 70% silencing of target genes in the liver without overt toxicity. But at 9 mg/kg, all animals died within 24 hours. At intermediate doses, researchers observed elevated inflammatory cytokines including IL-6, TNF-α, and IFN-γ, liver enzyme elevations, blood clotting abnormalities, and low platelet counts. These toxic responses occurred regardless of which siRNA sequence was used, confirming they were caused by the lipid vehicle itself, not the genetic payload.17Molecular Therapy. Mechanisms Underlying the Toxicity Associated with Microparticle Delivery Systems
This dose-dependent toxicity explains why the lipid chemistry matters so much. Newer ionizable lipids are specifically designed to be biodegradable, with ester bonds in their tails that can be cleaved by liver enzymes. Lipids like SM-102 (used in the Moderna vaccine) are hydrolyzed and cleared from the liver rapidly, while older lipids with more sterically hindered structures linger longer.18Molecular Therapy Methods & Clinical Development. Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism Faster clearance means less accumulation and a wider margin between therapeutic and toxic doses. The shift toward biodegradable ionizable lipids in nonhuman primates confirmed rapid hepatic clearance after a single dose.19PubMed. Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates
Manufacturing and the Cold Chain Challenge
Making lipid nanoparticles at scale is a precision problem. The particles self-assemble when an ethanol solution containing the lipids is rapidly mixed with an aqueous solution containing the nucleic acid. The speed and conditions of that mixing step determine the particle size. Research using microfluidic devices with chaotic mixer structures showed that the critical window for controlling size occurs in a narrow ethanol concentration range, and that particle size can be tuned in 10-nanometer increments by adjusting how long the mixture spends in that range, on timescales of tens of milliseconds.20PLOS ONE. Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers
Moving from lab-bench microfluidics to production-scale manufacturing has required ingenuity. One approach uses parallelized microfluidic platforms with 256 mixers operating simultaneously, achieving production rates of liters per hour while maintaining the same particle properties and mRNA delivery performance as lab-scale chips.21ACS Nano. Robust, Scalable Microfluidic Manufacturing of RNA–Lipid Nanoparticles Using Immobilized Antifouling Lubricant Coating Quality control throughout manufacturing is critical, with regulatory expectations requiring a polydispersity index (a measure of size uniformity) of 0.30 or below. Conventional batch methods often produce particles larger than 100 nanometers with inconsistent size distributions, requiring additional processing steps. Continuous microfluidic mixing offers better control and batch-to-batch consistency.22PubMed Central. Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development
Storage is the other bottleneck that became painfully visible during the COVID-19 vaccine rollout. LNPs are physically unstable over time: particle aggregation, lipid oxidation, and loss of encapsulation all erode potency. Formulations stored in buffer with 10% sucrose at −20°C can maintain their potency for at least 30 days, and lyophilization (freeze-drying) preserves bioactivity as well.23PubMed Central. Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines A large-scale analysis of over 600 formulations found that lyophilization becomes clearly protective only beyond 90 days of storage, which is the point at which median biological activity retention tends to drop below 80% in non-lyophilized preparations.24International Journal of Pharmaceutics. Storage stability of lipid nanoparticles: a curated benchmark dataset, systematic threshold analysis, and per-study machine learning prediction limits For global distribution, especially to warm-climate regions with limited cold chain infrastructure, developing thermostable LNP formulations remains a priority.
The Search for Better Ionizable Lipids
The ionizable lipid is the single most consequential ingredient in a lipid nanoparticle. It determines how efficiently the particle encapsulates cargo, how well it escapes endosomes, and how quickly it is cleared from the body. Researchers have synthesized and screened hundreds to thousands of candidate lipids. One large screen evaluated 465 ionizable lipids for mRNA delivery in cell culture, then narrowed to 42 candidates for in-depth study, revealing that both the acid-base properties (specifically the pKa, a measure of how easily the lipid picks up a charge) and the lipid’s buffering capacity predict how well a formulation delivers mRNA to the liver in living animals. That work expanded the acceptable pKa range to 6.2 through 7.4, broader than previously assumed.25PubMed Central. Structure-Activity Relationship of Ionizable Lipids for siRNA and mRNA Lipid Nanoparticle Design
Other groups have taken an entirely different chemical scaffold as their starting point. Over 250 novel ionizable lipids were synthesized based on piperazine, a core structure borrowed from the common laboratory buffer HEPES. After screening, the most promising candidates were tested in nonhuman primates carrying an influenza vaccine payload, where they generated functional antibody responses comparable to those from the industry-standard lipids MC3 and SM-102.26Biomaterials. Understanding structure activity relationships of Good HEPES lipids for lipid nanoparticle mRNA vaccine applications The diversity of chemical approaches is encouraging because it means the field is not locked into one lipid family. Different payloads, target organs, and dosing regimens may each benefit from lipids with distinct properties.
From Lab Curiosity to Sixty-Year Story
Lipid nanoparticles did not appear out of nowhere in 2020. Their development traces back through six decades of work on lipid-based nucleic acid delivery, beginning with early lipoplexes (complexes of permanently charged cationic lipids and DNA) and evolving through the critical innovation of ionizable cationic lipids, which carry charge only when needed.27PubMed. The 60-year evolution of lipid nanoparticles for nucleic acid delivery The first permanently charged lipids worked in cell culture but were too toxic and too quickly cleared for systemic use in animals. Ionizable lipids solved both problems: neutral at blood pH, they avoid triggering immune sensors in circulation but switch on their charge inside the acidic endosome. That single design insight, a lipid that is only charged when and where you need it to be, is arguably the breakthrough that made modern LNP therapeutics viable.
Today the delivery system is recognized not just as a passive wrapper but as an active participant in the immune response. For mRNA vaccines specifically, the LNP serves three roles simultaneously: protecting the fragile mRNA, enabling cellular uptake and endosomal release, and contributing its own adjuvant-like properties that help shape the immune response.28PubMed Central. Delivery Systems of mRNA Vaccines in the Treatment of Infectious Diseases: From Lipid Nanoparticles to Next-Generation Platforms That last point is underappreciated: the lipid shell is not immunologically inert. It activates certain innate immune pathways, which can boost the vaccine response but also contributes to the reactogenicity (the sore arm, fatigue, and fever) that many vaccine recipients experience. Understanding and tuning that built-in immune activation is an active area of research, particularly for applications where you want delivery without inflammation, like gene therapy for inherited diseases.